Treatment indications informed by a priori implant information

• US 20090157171A1
• Filed: 12/21/2007
• Published: 06/18/2009
• Est. Priority Date: 12/18/2007
• Status: Abandoned Application

• Current Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Ferren, Bran, Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Wood, Victoria Y.H., Leuthardt, Eric C.
• Application Number:
  US12/005,154
• Publication Number:
  US 20090157171A1
• Time in Patent Office: Days
• US Class Current: 623/1.420
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2039/2413 designed to reduce and or shut-off the flow when a certain maximum flow limit is exceeded
• CPC Class Codes: A61M 2039/242 designed to open when a predetermined pressure or flow rate has been reached, e.g. check valve actuated by fluid
• CPC Class Codes: A61M 2039/248 Ball-valve
• CPC Class Codes: A61M 2205/04 implanted
• CPC Class Codes: A61M 2205/3561 local, e.g. within room or hospital
• CPC Class Codes: A61M 2205/3592 using telemetric means, e.g. radio or optical transmission
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61M 39/24 Check- or non-return valves
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: G16H 20/17 delivered via infusion or injection
• CPC Class Codes: G16H 70/60 relating to pathologies

Abstract

Systems and methods are described for implementing or deploying therapeutic administration systems for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants; or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement; or obtaining one or more indications of a lactic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens; or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Claims

1-190. -190. (canceled)

191. A therapeutic administration system comprising:

a processor;

one or more instructions operable by the processor to obtain one or more indications of a lytic material in a vicinity of one or more body lumens; and

one or more instructions operable by the processor to cause an acceleration of a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens.

195. The therapeutic administration system of claim 191 in which the one or more instructions operable by the processor to cause the acceleration of the decrease in the local concentration of the lytic material in the vicinity of the one or more body lumens comprises:

one or more instructions operable by the processor to cause the acceleration of the portion of the lytic material to be drawn into an artificial vessel.

227. The therapeutic administration system of claim 191 in which the circuitry for obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

one or more instructions operable by the processor to cause at least a statin to be dispensed as the lytic material;

one or more instructions operable by the processor to obtain a concentration-indicative scalar of the one or more indications of the lytic material;

one or more instructions operable by the processor to cause a dispensation the lytic material into an upstream portion of the one or more body lumens;

one or more instructions operable by the processor to cause the lytic material to perfuse one or more organs in the vicinity of the one or more body lumens;

one or more instructions operable by the processor to signal at least one of the one or more indications of the lytic material via a wireless signal;

one or more instructions operable by the processor to detect a marker material indicative of the lytic material in the vicinity of the one or more body lumens;

one or more instructions operable by the processor to cause the lytic material to be urged into the one or more body lumens; and

one or more instructions operable by the processor to cause an acceleration of a dispensation of the lytic material transluminally into the one or more body lumens as a programmed response to one or more pathology-indicative signals.

192-194. -194. (canceled)

196-226. -226. (canceled)

228-268. -268. (canceled)

269. A therapeutic administration method comprising:

obtaining one or more indications of a lytic material in a vicinity of one or more body lumens; and

accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens.

270. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

causing at least a statin to be dispensed as the lytic material.

271. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

obtaining a concentration-indicative scalar of the one or more indications of the lytic material.

272. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

dispensing the lytic material into an upstream portion of the one or more body lumens.

273. The therapeutic administration method of claim 269 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

causing the portion of the lytic material to be drawn into an artificial vessel.

274. The therapeutic administration method of claim 269 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

reversing a flow direction of at least some of the lytic material.

275. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

permitting the lytic material to perfuse one or more organs in the vicinity of the one or more body lumens.

276. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

signaling at least one of the one or more indications of the lytic material via a wireless signal.

277. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

detecting a marker material indicative of the lytic material in the vicinity of the one or more body lumens.

278. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

causing the lytic material to be urged into the one or more body lumens.

279. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

accelerating a dispensation of the lytic material transluminally into the one or more body lumens as a programmed response to one or more pathology-indicative signals.

280. The therapeutic administration method of claim 269 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

causing the lytic material to be exposed to a lytic-material-absorbent element.

281. The therapeutic administration method of claim 269 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

causing the portion of the lytic material to be chemically deactivated.

282. The therapeutic administration method of claim 279 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

causing at least a statin to be dispensed as the lytic material.

283. The therapeutic administration method of claim 274 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

obtaining a concentration-indicative scalar of the one or more indications of the lytic material.

284. The therapeutic administration method of claim 277 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

dispensing the lytic material into an upstream portion of the one or more body lumens.

285. The therapeutic administration method of claim 275 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

causing the portion of the lytic material to be drawn into an artificial vessel.

286. The therapeutic administration method of claim 276 in which the accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens comprises:

reversing a flow direction of at least some of the lytic material.

287. The therapeutic administration method of claim 278 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

permitting the lytic material to perfuse one or more organs in the vicinity of the one or more body lumens.

288. The therapeutic administration method of claim 277 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

signaling at least one of the one or more indications of the lytic material via a wireless signal.

289. The therapeutic administration method of claim 281 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

detecting a marker material indicative of the lytic material in the vicinity of the one or more body lumens.

290. The therapeutic administration method of claim 279 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

causing the lytic material to be urged into the one or more body lumens.

291. The therapeutic administration method of claim 280 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

accelerating a dispensation of the lytic material transluminally into the one or more body lumens as a programmed response to one or more pathology-indicative signals.

292. The therapeutic administration method of claim 269 in which the obtaining one or more indications of a lytic material in a vicinity of one or more body lumens comprises:

causing at least a statin to be dispensed as the lytic material;

obtaining a concentration-indicative scalar of the one or more indications of the lytic material;

dispensing the lytic material into an upstream portion of the one or more body lumens;

permitting the lytic material to perfuse one or more organs in the vicinity of the one or more body lumens;

signaling at least one of the one or more indications of the lytic material via a wireless signal;

detecting a marker material indicative of the lytic material in the vicinity of the one or more body lumens;

causing the lytic material to be urged into the one or more body lumens; and

accelerating a dispensation of the lytic material transluminally into the one or more body lumens as a programmed response to one or more pathology-indicative signals.

293-322. -322. (canceled)